Pharmacogemonics and Risk Management

Year
1
Academic year
2018-2019
Code
02556082
Subject Area
Health Sciences and Technologies
Language of Instruction
Portuguese
Mode of Delivery
Face-to-face
Duration
SEMESTRIAL
ECTS Credits
6.0
Type
Compulsory
Level
2nd Cycle Studies - Mestrado

Recommended Prerequisites

All areas of life sciences. 

Teaching Methods

Exposing lectures. Discussion of case studies. Problems solving.

Learning Outcomes

To provide knowledge about the novel products e molecular therapeutic strategies resulting from genetic polimorphisms as well as about their impact on the variability to drug response. Role of pharmacogenomics on risk management associated to individualized therapeutics. Ethical and legal aspects.

Skills:

To provide competences on the application of pharmacogenomics to drug development and rationale drug dispensing.

Work Placement(s)

No

Syllabus

Pharmacogenomics

Introduction to single nucleotide polimorphism (SNPs)

Impact of genetic variability on drug response: pharmacokinetic and pharmacodynamic aspects

Risk management associated to drug use

Personalized therapeutics

Predictive medicine

Impact on drug discovery and rationale clinical trials design

Impact of pharmacogenomics on professional activities related to medicines

Legal and ethical issues.

Head Lecturer(s)

Sérgio Paulo Magalhães Simões

Assessment Methods

Assessment
Synthesis work: 15.0%
Clipping: 20.0%
Exam: 30.0%
Project: 35.0%

Bibliography

Strachan T, Read A,Human Molecular Genetics 3,Garland Science,Taylor and Francis, London,2003

Nebert DW, Vesell ES(2004) Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur J Pharmacol.,500,267-80

Brazeau DA(2004) Combining genome-wide and targeted gene expression profiling in drug discovery: microarrays and real-time PCR. Drug Discov Today.9,838-45

Thomas FJ, McLeod HL, Watters JW(2004) Pharmacogenomics: the influence of genomic variation on drug response. Curr Top Med Chem., 4, 1399-409

Villeneuve DJ, Parissenti AM(2004) The use of DNA microarrays to investigate the pharmacogenomicsof drug response in living systems. Curr Top Med Chem.,4,1329-45

Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H(2004) Pharmacogenetics: ethical problems and solutions. Nat Rev Genet.,5,676-80

Roses AD(2004) Pharmacogenetics and drug development:the path to safer and more effective drugs. Nat Rev Genet.5,645-56